Discovery of a Vorapaxar Analog with Increased Aqueous Solubility
Overview
Authors
Affiliations
An analog of the thrombin receptor antagonist vorapaxar (SCH 530348) with increased aqueous solubility, compound 9c (SCH 602539), was discovered through incorporation of polar substituents on the pyridine ring of the himbacine-derived lead series. This analog retained the excellent potency, pharmacokinetic and safety properties of vorapaxar while increasing the aqueous solubility by 20-fold. Also presented are in vivo evaluations of this compound in a cynomolgus monkey platelet aggregation assay and in a Folts model of thrombosis in anesthetized monkeys.
The domino effect triggered by the tethered ligand of the protease activated receptors.
Han X, Nieman M Thromb Res. 2020; 196:87-98.
PMID: 32853981 PMC: 7686079. DOI: 10.1016/j.thromres.2020.08.004.
Bokoch M, Jo H, Valcourt J, Srinivasan Y, Pan A, Capponi S Biochemistry. 2018; 57(39):5748-5758.
PMID: 30102523 PMC: 6584023. DOI: 10.1021/acs.biochem.8b00577.
Farag M, Patel H, Gorog D Drug Des Devel Ther. 2015; 9:3801-9.
PMID: 26229441 PMC: 4516206. DOI: 10.2147/DDDT.S68391.
Himbacine-derived thrombin receptor antagonists: c7-spirocyclic analogues of vorapaxar.
Chelliah M, Eagen K, Guo Z, Chackalamannil S, Xia Y, Tsai H ACS Med Chem Lett. 2014; 5(5):561-5.
PMID: 24900880 PMC: 4027741. DOI: 10.1021/ml500008w.
Chelliah M, Chackalamannil S, Xia Y, Greenlee W, Ahn H, Kurowski S ACS Med Chem Lett. 2014; 5(2):183-7.
PMID: 24900795 PMC: 4027727. DOI: 10.1021/ml400452v.